Status:
COMPLETED
NVAMD Satellite Study
Lead Sponsor:
Johns Hopkins University
Conditions:
Neovascular Age Related Macular Degeneration
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Intravitreal delivery of anti-vascular endothelial growth factor (VEGF) drugs has revolutionized the management of neovascular age-related macular degeneration (NVAMD). However, the requirement for ne...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Established diagnosis of NVAMD in one or both eyes
- Received 2 or more intravitreal injections of anti-VEGF therapy from the retinal physician during the prior 6 months
- Need for more therapy on a near monthly basis is anticipated
- Usual corrected visual acuity (UCVA) of at least one eye must be 20/200 or better
- Must be physically able to cooperate with OCT and other diagnostic imaging procedures
- Must be able to give informed consent and be able to complete telephone surveys
- Exclusion criteria:
- Systemic disease that can affect the peripheral retina (e.g., diabetes mellitus, sickle cell)
- History of symptomatic posterior vitreous detachment, retinal tear, or retinal detachment
- History of retinal surgery will not be enrolled.
Exclusion
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2016
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT02251366
Start Date
October 1 2014
End Date
October 30 2016
Last Update
August 31 2018
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Wilmer Eye Institute
Bel Air, Maryland, United States, 21014
2
Wilmer Eye Institute
Bethesda, Maryland, United States, 20814
3
Wilmer Eye Institute
Columbia, Maryland, United States, 21044
4
Wilmer Eye Institute
Frederick, Maryland, United States, 21702